Bayer AG v. Hetero Labs: Cardiovascular Patent Suit Dismissed With Prejudice
Bayer AG and Janssen Pharmaceuticals filed suit against Hetero Labs and co-defendants in Delaware District Court over US10828310B2, a patent covering cardiovascular risk reduction. The parties reached a mutual stipulated dismissal with prejudice in 182 days, with each side bearing its own costs and attorneys’ fees.
Bayer and Janssen’s cardiovascular patent suit ends by stipulation
On June 18, 2025, Bayer Pharma AG, Bayer AG, and Janssen Pharmaceuticals, Inc. filed a patent infringement action in the Delaware District Court against Hetero Labs Limited, Ascent Pharmaceuticals Inc., and Camber Pharmaceuticals, Inc. The suit centred on US10828310B2 (application no. US16/264032), a patent covering methods or compositions directed at reducing the risk of cardiovascular events. The case was assigned to Judge Richard G. Andrews, a highly experienced ANDA patent judge in Delaware.
The litigation concluded on December 17, 2025 — just 182 days after filing — when both sides filed a joint stipulation of dismissal with prejudice pursuant to Federal Rules of Civil Procedure 41(a)(1) and 41(c). The dismissal is mutual: Plaintiffs’ claims against Hetero and Hetero’s counterclaims against Plaintiffs are both extinguished. Each party agreed to bear its own legal costs. Dismissal with prejudice means neither side may re-litigate the same claims in federal court.
A resolution within six months, before meaningful claim construction or trial, is consistent with a negotiated commercial resolution — though the public record does not disclose whether a licence, consent judgment, or market access agreement underlies the dismissal. The mutual cost-bearing provision is a standard feature of confidential settlements in Hatch-Waxman matters. The terms governing Hetero’s ability to market a competing cardiovascular product remain unknown from the public docket.
Filing to Dismissed with Prejudice in 182 days
182 days — resolved well before typical ANDA patent trial timelines of 2–3 years
Stipulated dismissal with prejudice: what the ruling means for both parties
Dismissal with prejudice under Rules 41(a)(1) and 41(c)
A stipulated dismissal with prejudice under FRCP 41(a)(1) and 41(c) terminates all claims and counterclaims permanently. Neither Bayer/Janssen nor Hetero may re-file the same causes of action in federal court. Rule 41(c) extends this finality to Hetero’s counterclaims, ensuring both sides are equally foreclosed from re-litigation. The court did not adjudicate validity or infringement on the merits.
No merits rulingPatent survives — but on undisclosed terms
US10828310B2 was not found invalid or non-infringed. Bayer and Janssen retain the patent and its enforceability against third parties is unaffected by this dismissal. The absence of a validity challenge on the public record preserves the patent’s presumption of validity. Whether Hetero received a licence or agreed to a market entry date is not disclosed in the public docket, which is typical of Hatch-Waxman settlements.
Patent intact, terms confidentialHetero’s market path remains undisclosed
Hetero Labs and its co-defendants (Ascent Pharmaceuticals, Camber Pharmaceuticals) secured dismissal of the infringement claims against them, but on terms not visible in the public record. Dismissal with prejudice may reflect a licence agreement, an agreed-upon launch date, or other commercial arrangement. Hetero cannot re-assert counterclaims challenging the patent’s validity in this venue. Future challenge routes, including IPR at the USPTO, remain theoretically available.
Commercial terms undisclosedRapid resolution signals commercial drivers in ANDA litigation
Settlement within 182 days — before claim construction — suggests the parties identified a commercial resolution quickly. In Hatch-Waxman litigation, early dismissals with prejudice frequently accompany confidential licence agreements that control generic entry timing. Competitors holding ANDA applications for cardiovascular risk reduction products should monitor public Orange Book listings and any patent expiry disclosures that may follow. US10828310B2 remains a live enforcement asset for Bayer and Janssen.
Watch Orange Book listingsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bayer AG | Company | Pharmaceutical innovator — holder of US10828310B2 for cardiovascular risk reductionSearch in Eureka ↗ |
| Defendant | Hetero Labs, Ltd. | Company | Generic pharmaceutical manufacturer and ANDA applicant seeking market entrySearch in Eureka ↗ |
| Plaintiff counsel | Derek James Fahnestock | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Rodger Dallery Smith , II | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Bayer AGSearch in Eureka ↗ |
| Defendant counsel | Kenneth L. Dorsney. | Attorney | Counsel for Hetero Labs, Ltd.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Hetero Labs, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation invokes Rule 41(a)(1) for Plaintiffs’ claims and Rule 41(c) for Hetero’s counterclaims, creating a symmetric with-prejudice dismissal. The mutual cost-bearing provision — each side absorbs its own fees — is a strong marker of a negotiated resolution rather than a concession by either party. No validity, infringement, or claim construction determination was made, leaving the patent’s legal scope entirely intact for future enforcement against other parties.
US10828310B2 — Reducing the risk of cardiovascular events
US10828310B2, filed under application number US16/264032, protects technology in the cardiovascular pharmaceutical space, specifically directed at reducing the risk of cardiovascular events. The patent is held by Bayer and co-asserted with Janssen Pharmaceuticals, consistent with co-ownership or exclusive licensing arrangements common in major cardiovascular product franchises. The ‘310 patent’s application date and prosecution history would inform claim scope and potential design-around strategies for competitors.
Cardiovascular risk reduction remains one of the highest-value therapeutic areas in branded pharmaceuticals. A patent covering this indication — particularly one asserted against multiple generic manufacturers simultaneously — typically reflects a commercially significant product lifecycle extension strategy. For generic manufacturers, the ‘310 patent represents a key Paragraph IV certification hurdle. For Bayer and Janssen, it is a core enforcement asset whose continued validity and undisputed status (following this dismissal) strengthens the portfolio’s deterrent value against future ANDA filers.
Should you run an FTO against US10828310B2?
Any company developing or commercialising pharmaceutical compositions or methods targeting cardiovascular event risk reduction — including ANDA applicants, branded reformulators, and combination therapy developers — should assess freedom to operate against US10828310B2. This patent has been actively enforced against at least three generic manufacturers simultaneously. The case’s dismissal with prejudice does not diminish its enforceability; if anything, the absence of a validity ruling on the merits leaves the patent stronger.
PatSnap Eureka’s FTO Search Agent can map US10828310B2’s claim landscape against your product formulation or therapeutic method, identify prior art that may narrow its scope, and surface related family members or continuations that extend the risk perimeter. Eureka can also flag existing ANDA filers and paragraph IV certifications in the cardiovascular space, giving your R&D and regulatory teams a consolidated risk picture before committing to development expenditure.
Run a freedom-to-operate analysis on US10828310B2 to assess your product’s exposure
Run FTO in Eureka →Similar cardiovascular pharmaceutical patent cases in Delaware District Court
Explore related ANDA infringement actions involving cardiovascular patents litigated in Delaware District Court, including comparable stipulated dismissals and Hatch-Waxman outcomes.
What this case signals for the cardiovascular pharmaceutical IP landscape
Early dismissal in ANDA patent cases rarely means weakness — understanding the pattern matters for generic and branded competitors alike.
Pre-claim-construction settlement is the dominant Hatch-Waxman pattern
Over 70% of ANDA patent litigations in Delaware settle before trial, many before claim construction. Resolution in 182 days is consistent with parties reaching a licence or market-entry agreement early. Generic entrants and branded companies alike should price this litigation risk into ANDA development strategies from the outset.
Dismissal with prejudice protects Bayer’s patent from this defendant — not all
The with-prejudice dismissal binds Hetero Labs, Ascent, and Camber from re-litigating in federal court. It does not bar other ANDA filers from independently challenging US10828310B2 via IPR or a separate district court action. Bayer and Janssen should anticipate further challenges from other generic applicants.
Bayer v Hetero — key questions answered
The case was dismissed with prejudice by joint stipulation under FRCP Rules 41(a)(1) and 41(c) on December 17, 2025. All claims by Bayer, Bayer Pharma, and Janssen against Hetero Labs, Ascent Pharmaceuticals, and Camber Pharmaceuticals, and all counterclaims, were terminated. Each party bears its own costs and attorneys’ fees.
The patent asserted is US10828310B2 (application no. US16/264032), covering technology directed at reducing the risk of cardiovascular events. It was co-asserted by Bayer Pharma AG, Bayer AG, and Janssen Pharmaceuticals, Inc. against Hetero Labs and co-defendants.
No. The dismissal was by stipulation and did not involve any adjudication of validity or infringement. US10828310B2 retains its presumption of validity. The with-prejudice dismissal only bars Hetero Labs, Ascent, and Camber from re-litigating the same claims; other parties may still challenge the patent via IPR or separate district court actions.
The public record does not disclose the commercial terms. However, resolution in 182 days — before claim construction — is consistent with a confidential licence or market-entry date agreement, which is a common pattern in Hatch-Waxman ANDA litigation in Delaware. The mutual cost-bearing provision further suggests a negotiated commercial resolution rather than a litigated outcome.
The defendants were Hetero Labs Limited (the primary defendant), Ascent Pharmaceuticals Inc., and Camber Pharmaceuticals, Inc. All three were joined as ‘Hetero’ collectively in the stipulation. Their involvement together suggests a co-development, supply, or distribution arrangement related to a generic cardiovascular product under ANDA review.
PatSnap Eureka searches patents and litigation data to answer instantly.